Ali Shakeri-Zadeh, PhD
Highlights
Languages
- English
Gender
MaleJohns Hopkins Affiliations:
- Johns Hopkins School of Medicine Faculty
About Ali Shakeri-Zadeh
Primary Academic Title
Assistant Professor of Radiology and Radiological Science
Background
Dr. Shakeri-Zadeh is an Assistant Professor in the Department of Radiology. His research is focused on developing multifunctional nanostructures for theragnostic purposes. He has pioneered the development of folate-conjugated magneto-plasmonic nanoparticles for cancer imaging and therapy. Using multifunctional nanoplatforms he has applied different imaging modalities for treatment planning of nanoparticle-assisted cancer therapy. Since joining the Department of Radiology and the Cellular Imaging Section in ICE at Johns Hopkins University, he has been developing multimodal in vivo tracking of stem cells using BLI, CT, MRI, MPI, and MSOT. His current research interest is to combine nanotheranostic labeling of stem cells with image-guided therapy to develop new precision-based personalized methods for treating cancer and neurodegenerative diseases.
Recent News Articles and Media Coverage
-
Maryland Stem Cell Research Commission Announces $4 Million in Grants to Drive Stem Cell Innovations, Tedco (September 20, 2023)
Research Interests
Cell Labeling, In vivo Cell Tracking, Multimodal Imaging-Guided Therapy, Photothermal Therapy, Radiation Therapy, Nanomedicine, Theranostic Nanoparticles
Research Summary
Dr. Shakeri-Zadeh is the Principal Investigator of an active MSCRF/TEDCO grant (MSCRFL-6107) titled: Dynamic MPI Cytometry of Mesenchymal Stem Cells in a Mouse Model of MS. Using magnetic labeling of mesenchymal stem cells (MSCs) and in combination with MRI, quantitative dynamic MPI is used to address some fundamental queries about the fate of MSCs after intravenous, intraarterial, and intracerebroventricular injection in experimental autoimmune encephalomyelitis mice. Fast dynamic MPI at the time of injection is performed and then the mice are monitored over weeks. By analyzing data from this non-invasive imaging, neurological function tests, and post-mortem examinations for early and late time periods, it will be possible to determine how different MSC administration routes affect immunomodulation and remyelination in a mouse model of MS.
Patents
All-in-one Multimodal Nanotheranostic Platform for Image-Guided Therapy,
We have developed a novel all-in-one multimodal contrast agent usable in magnetic resonance imaging (MRI), magnetic particle imaging (MPI), magnetic-motive ultrasound (MMUS) imaging, (magneto)photoacoustic imaging (PAI) and computed tomography (CT). Moreover, the contrast agent doubles as a theranostic sensitizer for photothermal therapy, magnetic hyperthermia, high-intensity focused ultrasound (HIFU), and radiotherapy. Significantly, the invention’s compatibility with MPI, a novel imaging method projected to have widespread use in the near future, captures a new niche among current multimodal contrast agents. More details can be found here: https://jhu.technologypublisher.com/technology/48041
C17455
Honors
Early-stage investigator award; Alavi-Bradley symposium on molecular imaging and theranostics, University of Maryland, 1/1/22
Lectures & Presentations
- Gold-coated iron oxide nanoparticles in cancer nanotheranostics, Oral-Invited talk, Webinar, UNESCO-UNISA Africa Chair in Nanoscience and Nanotechnology, 10/12/22
- Magnetoplasmonic Nanoparticles as Cancer Theranostic Agents, Oral, Webinar, WMIS webinar, World Molecular Imaging Society (WMIS), 9/28/21
- MPI/MRI Cell Tracking of ALS Patient-Derived, Genome-Corrected iPSCs and iPSC-Derived Motor Neurons, Oral, Contrast Media Research Symposium, Annapolis, MD, USA, 8/21/22
- MPI/MRI of Cerebral Homing of SPIO-Labeled Stem Cells after Intra-Arterial Injection, Oral, The Future of Molecular MRI, Pasadena, CA, USA, 7/23/22
Memberships
- Active member, American Association for Cancer Research (AACR)